dpp-4

Popularity

500+ learners.

Translator
Examples

DPP-4 es la misma enzima que inactiva la GLP-1.	DPP4 is the same enzyme that inactivates GLP-1.
Algunos efectos secundarios de tomar inhibidores de DPP-4 pueden incluir náuseas y diarrea.	Some side effects from taking DPP-4 inhibitors may include nausea and diarrhea.
DPP-4 fue originalmente identificado como un antígeno de superficie en los linfocitos, CD26.	DPP4 was originally identified as the lymphocyte cell surface antigen CD26.
El alogliptin pertenece a una clase de medicamentos llamados inhibidores de la dipeptidil peptidasa-4 (DPP-4).	Alogliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors.
La saxagliptina pertenece a una clase de medicamentos llamados inhibidores de la dipeptidil peptidasa-4 (DPP-4).	Saxagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors.
La linagliptina pertenece a una clase de medicamentos llamados inhibidores de la dipeptidil peptidasa-4 (DPP-4).	Linagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors.
Pertenece a una clase de medicamentos llamados medicamentos inhibidores de la dipeptidil peptidasa-4 (DPP-4).	Sitagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors.
TESAVEL pertenece a una clase de antihiperglucemiantes orales que se denominan inhibidores de la dipeptidil-peptidasa 4 (DPP-4).	TESAVEL is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors.
Januvia pertenece a una clase de antihiperglucemiantes orales que se denominan inhibidores de la dipeptidil-peptidasa 4 (DPP-4).	Januvia is a member of a class of oral anti-hyperglycaemic agents called dipeptidyl peptidase 4 (DPP-4) inhibitors.
El medicamento actúa de este modo al bloquear una enzima específica (DPP-4) que es responsable de descomponer estas proteínas.	The medication does this by blocking a specific enzyme (DPP-4), which is responsible for breaking down these proteins.
La administración conjunta de IECA y un agente antidiabético, el inhibidor de la di-peptidil-peptidasa-4 (DPP-4), aumenta significativamente el riesgo de angioedema.	Co-administration of ACEI and an antidiabetic agent, dipeptidylptidase-4 (DPP-4) inhibitor, significantly increases the risk of angioedema.
La acción hormonal de GLP-1 se terminó rápidamente, como consecuencia de enzimática escisión por dipeptidylpeptidase IV (DPP IV o DPP-4).	The hormonal action of GLP-1 is rapidly terminated as a consequence of enzymatic cleavage by dipeptidylpeptidase IV (DPP IV or DPP4).
La vildagliptina, un inhibidor de la dipeptidil peptidasa 4 (DPP-4), actúa bloqueando la descomposición de las hormonas "incretinas" en el organismo.	Vildagliptin, which is a dipeptidyl peptidase 4 (DPP-4) inhibitor, works by blocking the breakdown of 'incretin' hormones in the body.
La sitagliptina es un inhibidor potente y muy selectivo de la enzima DPP-4 y, a concentraciones terapéuticas, no inhibe las enzimas estrechamente relacionadas DPP-8 ó DPP-9.	Sitagliptin is a potent and highly selective inhibitor of the enzyme DPP-4 and does not inhibit the closely-related enzymes DPP-8 or DPP-9 at therapeutic concentrations.
Sitagliptina Sitagliptina fosfato es un inhibidor muy selectivo, potente y activo por vía oral de la enzima dipeptidil peptidasa 4 (DPP-4) para el tratamiento de la diabetes tipo 2.	Sitagliptin Sitagliptin phosphate is an orally-active, potent, and highly selective inhibitor of the dipeptidyl peptidase 4 (DPP-4) enzyme for the treatment of type 2 diabetes.
Pertenece a una clase de fármacos conocidos como inhibidores de la dipeptidil peptidasa-4 (DPP-4), que funcionan aumentando la cantidad de sustancias naturales en el cuerpo, conocido como incretinas.	It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the amount of natural substances in the body, known as incretins.
Vildagliptina Vildagliptina actúa principalmente inhibiendo la dipeptidil peptidasa 4 (DPP-4), un enzima responsable de la degradación de las hormonas incretinas GLP-1 (péptido 1 similar al glucagón) y GIP (polipéptido insulinotrópico dependiente de glucosa).	Vildagliptin Vildagliptin acts primarily by inhibiting DPP-4, the enzyme responsible for the degradation of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
Vildagliptina actúa principalmente inhibiendo la dipeptidil peptidasa 4 (DPP-4), un enzima responsable de la degradación de las hormonas incretinas GLP-1 (péptido 1 similar al glucagón) y GIP (polipéptido insulinotrópico dependiente de glucosa).	Vildagliptin Vildagliptin acts primarily by inhibiting DPP-4, the enzyme responsible for the degradation of the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).
A pesar de estos resultados prometedores para demostrar el potencial de OXM en la tratamiento de la obesidad es importante tener en cuenta que OXM es un objetivo para inactivación por DPP-4 es tan GLP-1.	Although these results prove promising for the potential for OXM in the treatment of obesity it is important to note that OXM is a target for inactivation by DPP-4 just as is GLP-1.
Aunque al parecer los compuestos que inhiben la acción enzimática del DPP-4 son la mejor opción para el tratamiento de la hiperglicemia de una diabetes no controlada, hay varias consecuencias desconocidas asociadas a la inhibición del DPP-4.	Although targeting compounds that can inhibit the enzymatic action of DPP4 would seem like ideal candidates for treating the hyperglycemia of uncontrolled diabetes, there are several unknowns associated with DPP4 inhibition.